Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Diabetes Drug Warning

Diabetes Drug Warning News & Analysis News From the Food and Drug Administration Diabetes Drug Warning tion. The agency gave sirolimus an expe- Several drugs approved to treat type 2 dia- dited review because it can offer significant betes may lead to ketoacidosis, a serious improvement for a serious disease. The condition that may require hospitalization, medication also received orphan drug sta- the FDA has warned. tus because LAM is a rare illness. According The medications named in the safety to the US National Library of Medicine, only announcement—canagliflozin, dapagli- 2 to 5 women per 1 million women world- flozin, and empagliflozin—belong to the wide are known to have LAM. sodium-glucose cotransporter-2 (SGLT2) In a randomized clinical trial with 89 pa- inhibitor class of drugs that are FDA- tients, those who took sirolimus for 1 year approved for use with diet and exercise to had stabilized lung function, reduced se- lower blood glucose levels in adults with rumvascularendothelialgrowthfactorDlev- type 2 diabetes. The SGLT2 inhibitors els, and improved symptoms and quality of lower blood glucose levels by causing the life. The most commonly reported adverse kidneys to remove glucose from the body events associated with sirolimus during through urine. treatment for LAM were http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Diabetes Drug Warning

JAMA , Volume 314 (1) – Jul 7, 2015

Diabetes Drug Warning

Abstract

News & Analysis News From the Food and Drug Administration Diabetes Drug Warning tion. The agency gave sirolimus an expe- Several drugs approved to treat type 2 dia- dited review because it can offer significant betes may lead to ketoacidosis, a serious improvement for a serious disease. The condition that may require hospitalization, medication also received orphan drug sta- the FDA has warned. tus because LAM is a rare illness. According The medications named in the safety to the US...
Loading next page...
 
/lp/american-medical-association/diabetes-drug-warning-PSwb0DQ0yB
Publisher
American Medical Association
Copyright
Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2015.6849
Publisher site
See Article on Publisher Site

Abstract

News & Analysis News From the Food and Drug Administration Diabetes Drug Warning tion. The agency gave sirolimus an expe- Several drugs approved to treat type 2 dia- dited review because it can offer significant betes may lead to ketoacidosis, a serious improvement for a serious disease. The condition that may require hospitalization, medication also received orphan drug sta- the FDA has warned. tus because LAM is a rare illness. According The medications named in the safety to the US National Library of Medicine, only announcement—canagliflozin, dapagli- 2 to 5 women per 1 million women world- flozin, and empagliflozin—belong to the wide are known to have LAM. sodium-glucose cotransporter-2 (SGLT2) In a randomized clinical trial with 89 pa- inhibitor class of drugs that are FDA- tients, those who took sirolimus for 1 year approved for use with diet and exercise to had stabilized lung function, reduced se- lower blood glucose levels in adults with rumvascularendothelialgrowthfactorDlev- type 2 diabetes. The SGLT2 inhibitors els, and improved symptoms and quality of lower blood glucose levels by causing the life. The most commonly reported adverse kidneys to remove glucose from the body events associated with sirolimus during through urine. treatment for LAM were

Journal

JAMAAmerican Medical Association

Published: Jul 7, 2015

There are no references for this article.